A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in
adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102
800 mg on a BID basis - before breakfast and at bedtime - for 4 weeks and the same subjects
will be treated with SNC-102 1600mg in the morning and 800mg in the evening for an additional
4 weeks. Subjects will be assessed for changes in tic severity, safety, and pharmacokinetics.
The study hypothesis is that treatment with SNC-102 will improve the tic severity in adult
subjects with Tourette Syndrome.